Phase 1 Trial: RD795.34978 (REN001-105)
Latest Information Update: 29 Feb 2024
At a glance
- Drugs Mavodelpar (Primary)
- Indications Inborn error metabolic disorders; Mitochondrial myopathies
- Focus Pharmacokinetics
- Acronyms REN001-105
- Sponsors Reneo Pharmaceuticals
- 27 Feb 2024 Status changed from not yet recruiting to completed.
- 16 Oct 2023 Recruitment completion is expected on 11/10/2023 according to ISRCTN Clinical Trials Registry Record.
- 16 Oct 2023 New trial record